Opening book details…
Can I read Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis on EtoBox?
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis by Paul Karpecki; Victoria Barghout; Brad Schenkel; Lynn Huynh; Anamika Khanal; Brittany Mitchell; Mihran Yenikomshian; Enrico Zanardo; Cynthia Matossian is a Medicine article available to read on EtoBox.
What is Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis about?
## Background Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA^®^; OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restasis^®^; CsA), and lifitegrast ophthalmic solution 5% (Xiidra^®^; LFT) are anti-inflammatory agents indicated for DED. This analysis compared treatment patterns in patients with DED receiving OTX-101, CsA, or LFT. ## Methods This real-world, retrospective, longitudinal cohort study utilized Symphony Health Integrated Dataverse claims from July 2019 to June 2021. The dataset included all patients with OTX-101 claims and patients with CsA or LFT claims randomly selected 2:1 to OTX-101. Patients were sorted into 3 cohorts based on index treatment. Index date was that of first treatment claim, and follow-up period was from index date to end of clinical activity or data availability. Time to treatment discontinuation (TTD), probability of discontinuation, and treatment persistence were assessed for OTX-101 vs. CsA, then OTX-101 vs. LFT. Subgroup analysis was performed based on age and prior DED tre
Who reads Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Paul Karpecki; Victoria Barghout; Brad Schenkel; Lynn Huynh; Anamika Khanal; Brittany Mitchell; Mihran Yenikomshian; Enrico Zanardo; Cynthia Matossian
- Publisher
- Springer Science and Business Media LLC
- Published
- 2023
- Field
- Medicine (Health Sciences)